I will be informed of any new findings developed during the 
course of this clinical research study, which may relate to 
my willingness to continue participation in the study. 
9. I have been assured that confidentiality will be preserved 
except that qualified monitors from the Food and Drug 
Administration and the National Cancer Institute may review 
my records where appropriate and necessary. Qualified 
monitors shall include assignees authorized by the 
Surveillance Committee of this institution provided that 
confidentiality is assured and preserved. My name will not 
be revealed in any reports or publications resulting from 
this study, without my expressed consent. 
10. I have been informed that should I suffer any injury as a 
result of participation in this research activity, 
reasonable medical facilities are available at this 
institution. I understand, however, that I cannot expect to 
receive any credit or reimbursement for expenses from this 
institution or any financial compensation from this 
institution for such injury. 
11. I have been informed that I should inquire of the attending 
physician whether or not there are any services, 
investigational agents or devices, and/or medications being 
offered by the sponsor of the clinical research project at a 
reduced cost or without cost. Should the investigational 
agent become commercially available during the course of the 
study, I understand that I may be required to cover the cost 
of subsequent doses. 
Costs related to my medical care including expensive tests 
or procedures that may be specifically required by this 
clinical research study shall not be my responsibility. I 
have been given the opportunity to discuss the expenses or 
costs associated with my participation in this research 
activity. 
13. I understand that practicing effective contraception is 
medically necessary and a prerequisite for my participation 
in this clinical research study. Should contraception be 
interrupted or if there is any suspicion of pregnancy, my 
participation in this clinical research study will be 
terminated at the sole discretion of the investigator. 
14. I may discuss questions or problems during or after this 
study with Dr. Albert Deisseroth at (713) 792-8750. In 
addition, I may discuss any problems I may have or any 
questions regarding my rights during or after this study 
with the Chairman of the Surveillance Committee at (713) 
792-3220 and may in the event any problem arises during this 
clinical research contact the parties named above. 
[ 408 ] 
Recombinant DNA Research, Volume 16 
